Xanomeline-trospium chloride efficacy and safety studies in schizophrenia
Xanomeline-trospium is the first antipsychotic to treat schizophrenia without weight gain or neuromotor side effects. Xanomeline-trospium combination for schizophrenia is approved by United States FDA in September 2024.
The researchers carried out systematic review with random-effects meta-analysis on the efficacy and safety of xanomeline-trospium in randomized controlled trials in patients with schizophrenia.
They found xanomeline-trospium is an effective treatment for schizophrenia with a unique tolerability profile, potentially addressing unmet needs.
https://www.sciencedirect.com/science/article/pii/S0924977X24007879
